The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Jonathan W. Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb; Genentech; Gritstone Bio; Janssen; Jazz Pharmaceuticals; Lilly; Pfizer; Puma Biotechnology; Regeneron; Turning Point Therapeutics
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
JUNKO TANIZAKI
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Daiichi sankyo Co., Ltd.; EMD Serono/Merck; Janssen; Lilly Japan; MSD; Nihon Medi-Physics; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED
Speakers' Bureau - Abbvie; AstraZeneca Japan
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Summer Xia
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Christine Ratajczak
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Martha Li
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ellen Bolotin
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jabed Seraj
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Antonio Lugini
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; MSD; Roche; Sanofi/Regeneron